News
FDA approves ODD for selumetinib for treating neurofibromatosis type 1 (NF1): Merck
AstraZeneca and Merck, known as MSD outside the U.S. and Canada, announced that the U.S. FDA has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). ...
News
Merck disappoints by failing in phaseIII study of its drug which cures Alzheimer’s
The drug, verubecestat, was being tested in patients who showed only a glimmer of the symptoms that eventually rob them of memories and basic functions. It’s another setback in a long list of experimental treatments that have had little...
News
Oxford BioMedia could gain $100 million in sanofi invasion target
UK gene cell therapy designer Oxford BioMedica’s shares jumped as much as 11.2% to 12.30 pence this morning after announcing a $100 million collaboration and licence agreement with US hemophilia specialist Bioverativ , which last month agreed to be...
News
Pharma pioneer Sanofi guards its Dengvaxia
You do not get severe dengue from the vaccine. Just because you were administered with the vaccine means you’ll get infected. That’s s a little misinformation,” said Dr. Ruby Dizon, Sanofi Pasteur medical director. “You get...
News
Pfizer gets BREAKTHROUGH THERAPY designation from FDA for patients suffering with ATOPIC DERMATITIS
Pfizer Inc. (NYSE:PFE) today announced its once-daily oral Janus kinase 1 (JAK1) inhibitor PF-04965842 received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with moderate-to-severe atopic dermatitis (AD). ...
News
Pfizer invests $147M investment in portage
The world's largest pharmaceutical manufacturing plant is now 98,500 square feet larger.And that expansion -- the most visible part of an ongoing $147 million investment by Pfizer Inc. -- is a very good thing for Portage and Kalamazoo County,...
News
Apple, Intel, Merck, Pfizer, GE are Pimco’s Big buys
Pimco is the largest bond investor, but it also manages quite a bit in equities. According to S&P Capital IQ, Pimco now oversees $5.1 billion in U.S. equities. We spoke with Daniel Ivascyn, Pimco’s group chief...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















